ArticleInternational ophthalmology2025
Hemorrhagic complications in premature infants treated with intravitreal bevacizumab.
Article in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aims to evaluate the frequency of hemorrhagic complications and identify potential risk factors in premature infants treated with intravitreal bevacizumab for retinopathy of prematurity (ROP).
methodsThis retrospective study analyzed data from 132 premature infants treated with intravitreal bevacizumab for ROP. Hemorrhagic complications were categorized as preretinal or intravitreal based on clinical examination findings: preretinal hemorrhages were defined as bleeding confined to the ROP ridge and not exceeding two optic disc diameters, while intravitreal hemorrhages were defined as bleeding extending beyond two optic disc diameters into the vitreous cavity. Demographic and clinical variables, including gestational age, birth weight, maternal age, NICU length of stay, and the timing of anti-VEGF administration, were collected. Patients with pre-existing hemorrhages prior to treatment were excluded. Statistical analyses included descriptive methods, univariate comparisons, and binary logistic regression to identify independent risk factors for hemorrhagic complications.
resultsHemorrhagic complications were observed in 23 (17.4%) of the patients, with 91.3% being preretinal hemorrhages and 8.7% intravitreal hemorrhages. NICU length of stay was significantly longer in patients with bleeding (62.23 ± 12.87 days) compared to those without bleeding (45.78 ± 16.74 days, p < 0.0001). Logistic regression identified prolonged NICU stay as an independent risk factor for hemorrhagic complications, with each additional day increasing the risk by 5.1% (p = 0.008, OR = 1.051, 95% CI 1.013-1.091). Gestational age, birth weight, maternal age, and timing of anti-VEGF administration were not significantly associated with bleeding risk.
conclusionsThis study highlights the significant role of NICU length of stay in increasing the risk of hemorrhagic complications in premature infants treated with intravitreal bevacizumab. In retinopathy. of prematurity treated with bevacizumab, preretinal and vitreous hemorrhages are common. Each additional day of NICU stay increases the risk of hemorrhagic complications.
Indexed as
Identifiers
40540050What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.